Brief: Epigenomics Says Cumulative Loss Of More Than Half Of Nominal Share Capital Of Co Has Been Incurred
26/10/2020 09:02
Oct 26 (Reuters) - EPIGENOMICS AG ECXn.DE :
* EXECUTIVE BOARD NOTIFIES THAT ACCORDING TO ITS BEST
JUDGMENT A
CUMULATIVE LOSS OF MORE THAN HALF OF NOMINAL SHARE CAPITAL OF
COMPANY HAS BEEN INCURRED
* THIS ANTICIPATED DEVELOPMENT IS MAINLY ATTRIBUTABLE TO
BUDGETED
LOSSES FROM REGULAR BUSINESS OPERATIONS
Source text for Eikon: ID:nEQ99NYxha
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns